Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
06 2019
Historique:
received: 24 04 2018
revised: 02 07 2018
accepted: 02 08 2018
pubmed: 20 8 2018
medline: 27 6 2019
entrez: 20 8 2018
Statut: ppublish

Résumé

Cross-sectional data indicate that systemic inflammation is important in oesophageal adenocarcinoma. We conducted a prospective study to assess whether prediagnostic circulating markers of inflammation were associated with oesophageal adenocarcinoma and to what extent they mediated associations of obesity and cigarette smoking with cancer risk. This nested case-control study included 296 oesophageal adenocarcinoma cases and 296 incidence density matched controls from seven prospective cohort studies. We quantitated 69 circulating inflammation markers using Luminex-based multiplex assays. Conditional logistic regression models estimated associations between inflammation markers and oesophageal adenocarcinoma, as well as direct and indirect effects of obesity and smoking on risk of malignancy. Soluble tumour necrosis factor receptor 2 (sTNFR2) (ORs This prospective study provides evidence of a link between systemic inflammation and oesophageal adenocarcinoma risk. In addition, this study provides the first evidence that indirect effects of excess adiposity and cigarette smoking, via systemic inflammation, increase the risk of oesophageal adenocarcinoma.

Identifiants

pubmed: 30121626
pii: gutjnl-2018-316678
doi: 10.1136/gutjnl-2018-316678
pmc: PMC6379150
mid: NIHMS1004548
doi:

Substances chimiques

Biomarkers, Tumor 0
Inflammation Mediators 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

960-968

Subventions

Organisme : NCI NIH HHS
ID : U01 CA167462
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA CP010220-08
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA063673
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA182883
Pays : United States
Organisme : Cancer Research UK
ID : C570/A11692
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K07 CA187403
Pays : United States
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA182883
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167462
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Cancer. 2017 Feb 1;140(3):600-610
pubmed: 27770434
PLoS One. 2014 Jul 30;9(7):e103508
pubmed: 25075959
Curr Opin Pharmacol. 2009 Dec;9(6):721-6
pubmed: 19828375
Arch Med Sci. 2013 Apr 20;9(2):191-200
pubmed: 23671428
Clin Gastroenterol Hepatol. 2013 Aug;11(8):934-43
pubmed: 23466711
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9077-82
pubmed: 22603795
JAMA. 2013 Oct 2;310(13):1353-68
pubmed: 24084921
Nat Rev Cancer. 2010 Feb;10(2):87-101
pubmed: 20094044
Cancer Lett. 2016 Jan 1;370(1):117-24
pubmed: 26519754
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2840-9
pubmed: 25249326
Gut. 2017 Sep;66(9):1542-1554
pubmed: 27694141
Cancer Epidemiol. 2011 Aug;35(4):309-19
pubmed: 21470937
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L119-28
pubmed: 26001775
Am J Gastroenterol. 2006 Nov;101(11):2619-28
pubmed: 16952280
Cytokine. 2015 May;73(1):84-90
pubmed: 25743242
Clin Gastroenterol Hepatol. 2012 Jul;10(7):728-34; quiz e61-2
pubmed: 22433923
Obesity (Silver Spring). 2011 Feb;19(2):402-8
pubmed: 20948514
Carcinogenesis. 2017 Oct 26;38(11):1104-1111
pubmed: 28968774
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Cancer. 2002 May 1;94(9):2490-501
pubmed: 12015775
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393-403
pubmed: 25106775
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5
pubmed: 15767340
Psychoneuroendocrinology. 2013 Feb;38(2):179-87
pubmed: 22727479
Pancreatology. 2012 Jul-Aug;12(4):344-9
pubmed: 22898636
Br J Surg. 2010 Jul;97(7):1028-34
pubmed: 20632268
J Natl Cancer Inst. 2005 Mar 16;97(6):433-8
pubmed: 15770007
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1902-11
pubmed: 21715603
J Natl Cancer Inst. 2015 Jul 28;107(10):
pubmed: 26220734
J Natl Cancer Inst. 2010 Sep 8;102(17):1344-53
pubmed: 20716718
Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72
pubmed: 25169849
Am J Gastroenterol. 2008 Feb;103(2):292-300
pubmed: 17986313
Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):501-508
pubmed: 29195669
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1384-92
pubmed: 25973022
Cancer Res. 2005 Apr 15;65(8):3146-54
pubmed: 15833844
Trends Cell Biol. 2016 Apr;26(4):249-261
pubmed: 26791157
N Engl J Med. 2003 Jul 17;349(3):215-24
pubmed: 12824459
Eur J Immunol. 2010 Apr;40(4):1099-106
pubmed: 20127680
Curr Med Res Opin. 2015 Mar;31(3):557-74
pubmed: 25651481
Dig Surg. 2012;29(3):251-60
pubmed: 22868386
J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50
pubmed: 15572756
Int J Epidemiol. 2012 Dec;41(6):1706-18
pubmed: 23148106
Nat Rev Immunol. 2009 May;9(5):377-84
pubmed: 19330016
PLoS One. 2008;3(10):e3534
pubmed: 18953412
Blood. 2013 Aug 8;122(6):951-7
pubmed: 23814017

Auteurs

Michael B Cook (MB)

Division of Cancer Epidemiology and Genetics, NIH, DHHS, National Cancer Institute, Rockville, Maryland, USA.

Matthew J Barnett (MJ)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Cathryn H Bock (CH)

Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.

Amanda J Cross (AJ)

Department of Epidemiology and Biostatistics, Imperial College London, London, UK.

Phyllis J Goodman (PJ)

Southwest Oncology Group (SWOG) Statistics & Data Management Center (SDMC), Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Gary E Goodman (GE)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Swedish Medical Center, Swedish Cancer Institute, Seattle, Washington, USA.

Christopher A Haiman (CA)

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Kay-Tee Khaw (KT)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Marjorie L McCullough (ML)

Department of Public Health and Primary Care, American Cancer Society Inc, Atlanta, Georgia, USA.

Christine C Newton (CC)

Department of Public Health and Primary Care, American Cancer Society Inc, Atlanta, Georgia, USA.

Marie-Christine Boutron-Ruault (MC)

CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Paris, France.
Generations and Health, Gustave Roussy, Villejuif, France.

Eiliv Lund (E)

Department of Community Medicine, UiT The Arctic University of Norway, Tromso, Norway.

Martin Rutegård (M)

Department of Surgical and Perioperative Sciences, Umea University, Umea, Sweden.

Mark D Thornquist (MD)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Michael Spriggs (M)

Information Management Services (IMS), Rockville, Maryland, USA.

Carol Giffen (C)

Information Management Services (IMS), Rockville, Maryland, USA.

Neal D Freedman (ND)

Division of Cancer Epidemiology and Genetics, NIH, DHHS, National Cancer Institute, Rockville, Maryland, USA.

Troy Kemp (T)

Human Papilloma Virus (HPV) Immunology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.

Candyce H Kroenke (CH)

Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Loïc Le Marchand (L)

Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.

Jin Young Park (JY)

Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France.

Michael Simon (M)

Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.

Lynne R Wilkens (LR)

Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Ligia Pinto (L)

Information Management Services (IMS), Rockville, Maryland, USA.

Allan Hildesheim (A)

Division of Cancer Epidemiology and Genetics, NIH, DHHS, National Cancer Institute, Rockville, Maryland, USA.

Peter T Campbell (PT)

Department of Public Health and Primary Care, American Cancer Society Inc, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH